Check out Full Prescribing Details OPDIVO® (nivolumab) is indicated to the treatment of adult patients with classical Hodgkin lymphoma (cHL) which has relapsed or progressed just after autologous hematopoietic stem mobile transplantation (HSCT) and brentuximab vedotin or immediately after 3 or maybe more lines of systemic therapy that includes aut